Form 4: Ocuphire Pharma CFO Nirav S. Jhaveri Reports Transaction in Company Stock
SEC Form 4 Filing
Nirav S. Jhaveri, CFO of Ocuphire Pharma, Inc., reports the purchase and disposal of company stock on March 21, 2024.
Summary
- On March 21, 2024, Nirav S. Jhaveri, the Chief Financial Officer of Ocuphire Pharma, Inc., engaged in a transaction involving the company's common stock.
- Jhaveri purchased 10,000 shares of common stock at a price of $2.1 per share.
- Following the reported transaction, Jhaveri directly owns 150,000 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction by a company insider, and does not inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.
Stakeholder Impact
- The transaction provides shareholders with insight into the actions of a key company executive.
Key Dates
| Date | Description |
|---|---|
| 03/21/2024 | Date of stock purchase and disposal transaction. |
| 03/25/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.